Actinium Pharmaceuticals Inc. (ATNM) Downgraded to “Hold” at Zacks Investment Research
Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
A number of other research analysts also recently issued reports on ATNM. Roth Capital initiated coverage on shares of Actinium Pharmaceuticals in a research report on Thursday, August 25th. They issued a “buy” rating and a $5.00 price target on the stock. FBR & Co set a $9.00 price target on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 21st.
Shares of Actinium Pharmaceuticals (NYSEMKT:ATNM) traded down 5.62% during midday trading on Tuesday, hitting $1.14. 843,535 shares of the stock traded hands. The firm has a 50-day moving average price of $1.64 and a 200-day moving average price of $1.77. Actinium Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $3.50. The stock’s market capitalization is $54.40 million.
In related news, major shareholder Sloan-Kettering Cance Memorial sold 192,927 shares of the business’s stock in a transaction on Wednesday, August 31st. The shares were sold at an average price of $1.83, for a total transaction of $353,056.41. Following the transaction, the insider now owns 4,878,988 shares in the company, valued at approximately $8,928,548.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Hedge funds have recently made changes to their positions in the stock. BlackRock Fund Advisors raised its stake in shares of Actinium Pharmaceuticals by 31.5% in the second quarter. BlackRock Fund Advisors now owns 102,003 shares of the company’s stock worth $181,000 after buying an additional 24,453 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth approximately $247,000. BlackRock Institutional Trust Company N.A. raised its stake in shares of Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock worth $819,000 after buying an additional 47,131 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock worth $2,798,000 after buying an additional 254,318 shares during the period.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Stock Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.